Nanotherapeutic Interventions in Diabetic Wound Healing: Biomarker- Guided Mechanisms and Translational Prospects

INTRODUCTION: Diabetes mellitus is a chronic metabolic disorder that is frequently complicated by impaired wound healing, resulting in diabetic foot ulcers, amputations, and long-term disability. Conventional wound management strategies often fail due to persistent inflammation, oxidative stress, vascular dysfunction, and neuropathy. Recent advances in nanotechnology and biomarker research have emerged as promising approaches to improve diabetic wound healing outcomes. METHODS: A comprehensive literature review was conducted using PubMed, ScienceDirect, Elsevier, Web of Science, and Google Scholar to identify relevant studies published up to January 2025. Peerreviewed original research articles and reviews were screened using keywords related to diabetic wound healing, nanotherapeutics, nanoparticles, biomarkers, tissue engineering, and clinical translation. RESULTS: Nanotherapeutic systems, including metallic nanoparticles, polymeric nanoparticles, nanofibres, lipid-based carriers, hydrogels, and bioengineered exosomes, have demonstrated antimicrobial, pro-angiogenic, anti-inflammatory, and antioxidant effects in preclinical and clinical studies. These systems promote accelerated wound closure, enhance collagen deposition, improve angiogenesis, and reduce the inflammatory burden. Additionally, emerging biomarkers, such as microRNAs, cytokines, and angiogenic factors, provide valuable insights into wound progression, therapeutic response, and tissue regeneration. The integration of biomarker monitoring with nanocarrier-based delivery systems supports a personalised and adaptive wound care strategy. DISCUSSION: The combined application of nanotherapeutics and biomarker-based diagnostics addresses key pathological barriers in diabetic wound healing and offers improved therapeutic precision. However, translational challenges remain, including biosafety concerns, long-term toxicity, regulatory complexities, and variability in clinical outcomes. CONCLUSION: Nanotechnology-based therapeutics integrated with biomarker-driven assessment represent a promising and evolving paradigm for DM wound management, with the potential to enhance healing efficiency and support personalised treatment approaches; further large-scale clinical validation is warranted.